Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2016 12:39 ET | Source: Alaunos Therapeutics, Inc.

ZIOPHARM Announces Two Oral Presentations at ASGCT 19th Annual Meeting

BOSTON, April 18, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced results from two programs will...
March 31, 2016 07:00 ET | Source: Alaunos Therapeutics, Inc.

ZIOPHARM to Present at the Jefferies 2nd Annual Immuno-Oncology Summit

BOSTON, March 31, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2nd...
March 09, 2016 08:14 ET | Source: Alaunos Therapeutics, Inc.

Molecular Therapy Publication Highlights Sleeping Beauty Potential in Personalized TCR Gene Therapy

BOSTON, March 09, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the publication of an article...
February 24, 2016 16:56 ET | Source: Alaunos Therapeutics, Inc.

ZIOPHARM Reports Fourth-Quarter 2015 Financial Results and Provides Update on Recent Activities

BOSTON, Feb. 24, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the fourth quarter ended December 31, 2015, and provided an update on the...
February 24, 2016 07:00 ET | Source: Alaunos Therapeutics, Inc.

ZIOPHARM Announces First Patient Treated in the Dose Escalation Portion of the Phase 1 Study of Ad-RTS-hIL-12 for Advanced Glioma

BOSTON, Feb. 24, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that, following the successful...
February 23, 2016 07:00 ET | Source: Alaunos Therapeutics, Inc.

ZIOPHARM Announces Publication in Scientific Reports Describing Genetic Editing of Human Leukocyte Antigen in Cell Therapies to Broaden Their Human Application

BOSTON, Feb. 23, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the publication of a study in...
February 09, 2016 07:00 ET | Source: Alaunos Therapeutics, Inc.

ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies

BOSTON, Feb. 09, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that the first patient has been...
February 02, 2016 07:00 ET | Source: Alaunos Therapeutics, Inc.

ZIOPHARM to Present at the 18th Annual BIO CEO & Investor Conference

BOSTON, Feb. 02, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 18th Annual BIO CEO...
January 11, 2016 07:00 ET | Source: Alaunos Therapeutics, Inc.

ZIOPHARM Announces Sleeping Beauty Non-Viral Gene Transfer Technology Featured in Nature Medicine

BOSTON, Jan. 11, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that its Sleeping Beauty...
January 06, 2016 07:00 ET | Source: Alaunos Therapeutics, Inc.

ZIOPHARM to Present at the 34th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence J.N. Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 34th Annual...